Hospital
Deaconess Union County Hospital, INC
Deaconess Union County Hospital, INC was paid $10.10M by Medicaid between Jan 2018 and Dec 2024, across 112 billing codes. Its largest line is 99284, emergency room visit (serious) — 22% of everything it billed.
33Billing provider infoDEACONESS UNION COUNTY HOSPITAL, INC
MORGANFIELD, KY 42437
MORGANFIELD, KY 42437
33aNPI1497320519assigned 05/21/2021
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$10.10M
24GClaims158,330
24DCodes billed112
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WATHEN, CHERYL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 27,753 | $1.14M | |
| 2019 | 26,398 | $997K | |
| 2020 | 13,285 | $545K | |
| 2021 | 8,056 | $571K | |
| 2022 | 32,548 | $2.30M | |
| 2023 | 28,166 | $2.51M | |
| 2024incomplete | 22,124 | $2.04M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 5,779 | 4,504 | $2.27M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 12,174 | 10,092 | $2.02M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.4% | 2,289 | 1,364 | $848K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.8% | 612 | 540 | $684K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.6% | 1,107 | 898 | $360K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 3.4% | 2,834 | 2,421 | $340K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.3% | 7,617 | 1,630 | $330K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.1% | 401 | 352 | $312K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.0% | 2,987 | 2,367 | $203K |
| 80053 | Comprehensive metabolic panel | 1.8% | 13,224 | 8,923 | $184K |
| 71045 | Radiologic examination, chest; single view | 1.6% | 2,188 | 1,811 | $161K |
| 36415 | Collection of venous blood by venipuncture | 1.3% | 21,898 | 9,430 | $128K |
100 more codes
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 2,204 | $127K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.2% | 2,315 | $121K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 11,452 | $119K |
| 80050 | General health panel | 1.1% | 2,070 | $111K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.1% | 2,284 | $110K |
| G0378 | Hospital observation service, per hour | <1% | 872 | $100K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,309 | $88K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,680 | $87K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 868 | $76K |
| 84484 | <1% | 2,656 | $75K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 776 | $67K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,116 | $66K |
| 80061 | Lipid panel | <1% | 1,904 | $51K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 592 | $51K |
| 81001 | <1% | 5,240 | $51K | |
| 83735 | <1% | 3,404 | $50K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,268 | $49K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,620 | $49K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,158 | $45K |
| 83690 | <1% | 2,213 | $39K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 893 | $39K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 567 | $37K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 497 | $34K |
| 87040 | <1% | 597 | $33K | |
| 84439 | <1% | 2,264 | $32K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 720 | $31K |
| 82607 | <1% | 746 | $28K | |
| 83605 | <1% | 915 | $25K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,525 | $23K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 290 | $22K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,448 | $22K |
| 83874 | <1% | 1,102 | $21K | |
| 82550 | <1% | 1,438 | $19K | |
| 73630 | <1% | 164 | $17K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,081 | $17K |
| 84703 | <1% | 837 | $15K | |
| 82553 | <1% | 935 | $15K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 263 | $15K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,196 | $14K |
| 81025 | <1% | 860 | $13K | |
| 87430 | <1% | 750 | $13K | |
| 97014 | <1% | 425 | $13K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 120 | $13K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 676 | $12K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,018 | $11K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 737 | $10K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 451 | $10K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 163 | $10K |
| 87081 | <1% | 314 | $10K | |
| 83540 | <1% | 508 | $9K | |
| 82150 | <1% | 769 | $9K | |
| 96376 | <1% | 152 | $9K | |
| 73610 | <1% | 73 | $8K | |
| 82728 | <1% | 231 | $8K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 270 | $7K |
| 87077 | <1% | 1,114 | $7K | |
| 83550 | <1% | 305 | $7K | |
| 87186 | <1% | 634 | $7K | |
| 86803 | <1% | 164 | $6K | |
| 85379 | <1% | 223 | $6K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 74 | $6K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 26 | $5K |
| 94760 | <1% | 299 | $5K | |
| 97162 | <1% | 48 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,153 | $4K |
| 82947 | <1% | 312 | $4K | |
| 85610 | <1% | 433 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,174 | $3K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 167 | $3K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 225 | $3K |
| 81015 | <1% | 510 | $3K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 50 | $3K |
| 85652 | <1% | 302 | $2K | |
| 81003 | <1% | 432 | $2K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 160 | $2K |
| 74022 | <1% | 16 | $2K | |
| 82746 | <1% | 38 | $2K | |
| 82077 | <1% | 96 | $2K | |
| 86140 | <1% | 133 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 103 | $2K |
| 82043 | <1% | 84 | $2K | |
| 97161 | <1% | 13 | $2K | |
| 73030 | <1% | 20 | $2K | |
| 80076 | <1% | 63 | $1K | |
| 73130 | <1% | 18 | $1K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 67 | $1K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 14 | $963.61 |
| 82248 | <1% | 151 | $946.49 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 275 | $906.05 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 14 | $896.40 |
| J3490 | Unclassified drugs | <1% | 14 | $821.38 |
| 87420 | <1% | 17 | $533.31 | |
| 85027 | <1% | 53 | $497.99 | |
| 83880 | <1% | 20 | $425.79 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 37 | $292.63 |
| 85007 | <1% | 34 | $191.10 | |
| 87070 | <1% | 13 | $183.90 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 98 | $130.80 |
| J2704 | Injection, propofol, 10 mg | <1% | 13 | $76.40 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 15 | $7.96 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWATHEN, CHERYL (CFO)
| Provider | Location | Paid |
|---|---|---|
| Deaconess Clinic, INC | Newburgh, IN | $6.54M |
| Deaconess Hospital, INC | Evansville, IN | $5.62M |
| Deaconess Hospital, INC | Newburgh, IN | $3.36M |
| Deaconess Hospital, INC | Evansville, IN | $3.30M |
| Deaconess Clinic, INC | Evansville, IN | $3.09M |
| Deaconess Hospital, INC. | Evansville, IN | $2.52M |
| Deaconess Clinic, INC | Newburgh, IN | $2.09M |
| Deaconess Hospital, INC | Evansville, IN | $2.06M |
| Deaconess Hospital, INC | Evansville, IN | $1.56M |
| Deaconess Clinic, INC | Evansville, IN | $1.56M |
| Deaconess Clinic, INC. | Princeton, IN | $1.55M |
| Deaconess Clinic INC. | Evansville, IN | $1.32M |
| Deaconess Hospital, INC | Newburgh, IN | $1.27M |
| Deaconess Clinic INC | Evansville, IN | $1.15M |
| Deaconess Clinic, INC | Boonville, IN | $1.15M |
| Deaconess Clinic INC | Owensboro, KY | $957K |
| Deaconess Clinic, INC | Henderson, KY | $911K |
| Deaconess Specialty Physicians, INC | Evansville, IN | $885K |
| Deaconess Clinic, INC | Petersburg, IN | $872K |
| Deaconess Clinic INC. | Evansville, IN | $828K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.